Drugs Made In America Acquisition Corp. Ordinary Shares Financial Flexibility Index
Drugs Made In America Acquisition Corp. Ordinary Shares financial flexibility index. Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) has a Financial Flexibility Index of -0.03x as of June 2026. Free cash flow of $-244.60K (operating CF $-244.61K minus capex $3.00) represents 0% of total liabilities ($9.14 Million). See Drugs Made In America Acquisition Corp. free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of Drugs Made In America Acquisition Corp. Ordinary Shares (2024–2025)
Financial flexibility index of Drugs Made In America Acquisition Corp. Ordinary Shares from 2024 to 2025. Historical Financial Flexibility Index trend for Drugs Made In America Acquisition Corp. Ordinary Shares across 2 annual periods. Check Drugs Made In America Acquisition Corp. cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Drugs Made In America Acquisition Corp. Ordinary Shares Financial Flexibility Index by Year (2024–2025)
Drugs Made In America Acquisition Corp. Ordinary Shares financial flexibility index by year from 2024 to 2025. Year-by-year free cash flow to debt coverage for Drugs Made In America Acquisition Corp. Ordinary Shares. For the full cash flow conversion analysis, see Drugs Made In America Acquisition Corp. cash flow conversion.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -0.07x | $-539.19K | $-539.19K | $7.28 Million | ▲ +100.0% |
| 2024 | -216.50x | $-172.26K | $-172.26K | $795.67 | — |